Story perspectives

Eli Lilly to Buy AtaiBeckley for $3.8B, FDA Grants Breakthrough

7/17/2026

Summary

Lilly Acquires AtaiBeckley

Eli Lilly agreed to acquire AtaiBeckley for $6.75 per share in cash, with up to $2.50 per share in milestones, valuing the deal at roughly $3.8 billion.
BPL-003, a synthetic 5-MeO-DMT nasal spray for treatment-resistant depression, earned FDA Breakthrough Therapy Designation after a Phase 2b trial showed two-day improvement.
The deal should close in Q3 2026 pending shareholder and regulatory approval.

Summary

Trump Accelerates Psychedelics

President Donald Trump issued an April executive order directing U.S. health regulators to speed reviews and boost federal funding for psychedelic-based treatments.
AtaiBeckley was formed in 2025 by merging Germany-based Atai Life Sciences with privately held Beckley Psytech.
Venture capitalist Peter Thiel provided early financing for AtaiBeckley’s psychedelic program.
Lilly’s deal follows a $7.8 billion Centessa acquisition and a plan to spend over $10 billion upfront, up to $25 billion this year.

Summary

Kenya Mirrors FDA

Kenya's Pharmacy and Poisons Board will base its psychedelic guidelines on U.S. Food and Drug Administration (FDA) approvals.
Analysts estimate a single DMT session could cut long-term costs for Kenya's Social Health Insurance Fund.
Nairobi ethicists warn that high fees of thousands of dollars per guided session may restrict treatment to elite private hospitals.
Lilly’s deal is expected to increase lobbying for rapid psychedelic approvals, influencing African health policies.

History

Historical Context

The FDA’s 5 March 2019 approval of Janssen’s Spravato nasal spray marked the first U.S. psychedelic-derived antidepressant, building on ketamine’s 1962 synthesis and the 2000 discovery of its rapid antidepressant action. Earlier breakthrough designations in 2013 and 2016 and a 2019 EMA approval spurred broader regulatory interest worldwide. Its REMS-restricted use and cost concerns fuel ongoing debate.

1 of 4

Lilly Acquires AtaiBeckley

Eli Lilly agreed to acquire AtaiBeckley for $6.75 per share in cash, with up to $2.50 per share in milestones, valuing the deal at roughly $3.8 billion.
BPL-003, a synthetic 5-MeO-DMT nasal spray for treatment-resistant depression, earned FDA Breakthrough Therapy Designation after a Phase 2b trial showed two-day improvement.
The deal should close in Q3 2026 pending shareholder and regulatory approval.

1 / 4